SCHEMBL6061920

SCHEMBL6061920

CC(C)=CCC/C(C)=C/CC/C(C)=C/COC/C=C(\C)CC/C=C(\C)CCC=C(C)C

nearest known ligand 0.70

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.70
ALOX15 P16050 3/20 0.62
ALDH1A1 P00352 2/20 0.62
MAPT P10636 2/20 0.61
MEN1 O00255 2/20 0.61
CYP3A4 P08684 2/20 0.61
UGT1A1 P22309 1/20 0.61
SQLE Q14534 3/20 0.59
FNTA P49354 5/20 0.58
FNTB P49356 3/20 0.58
KDM4E B2RXH2 1/20 0.55
PGGT1B P53609 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5320561 1.00 KMT2A (0.70) KMT2AALOX15ALDH1A1MAPTMEN1
SCHEMBL28008995 1.00 KMT2A (0.70) KMT2AALOX15ALDH1A1MAPTMEN1
SCHEMBL19873084 1.00 KMT2A (0.70) KMT2AALOX15ALDH1A1MAPTMEN1
SCHEMBL11851208 1.00 KMT2A (0.70) KMT2AALOX15ALDH1A1MAPTMEN1
SCHEMBL30531902 1.00 KMT2A (0.70) KMT2AALOX15ALDH1A1MAPTMEN1
SCHEMBL28854298 0.98 KMT2A (0.65) KMT2AALOX15ALDH1A1MAPTMEN1
SCHEMBL3400313 0.98 KMT2A (0.65) KMT2AALOX15ALDH1A1MAPTMEN1
SCHEMBL492962 0.98 KMT2A (0.65) KMT2AALOX15ALDH1A1MAPTMEN1
SCHEMBL27649625 0.98 KMT2A (0.65) KMT2AALOX15ALDH1A1MAPTMEN1
SCHEMBL492960 0.98 KMT2A (0.65) KMT2AALOX15ALDH1A1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230321228-A1 VACCINE ADJUVANTS AND METHODS OF SYNTHESIZING AND USING THE SAME EUAGORE, LLC 2023-10-12 US disclosed
US-20230321228-A1 VACCINE ADJUVANTS AND METHODS OF SYNTHESIZING AND USING THE SAME EUAGORE, LLC 2023-10-12 US disclosed
WO-2022011031-A1 VACCINE ADJUVANTS AND METHODS OF SYNTHESIZING AND USING THE SAME Amyris, Inc. (US) 2022-01-13 WO disclosed
EP-3013925-B1 LUBRICATING COMPOSITIONS CONTAINING ISOPRENE BASED COMPONENTS CASTROL LTD (GB) 2019-08-07 EP disclosed
US-20160137945-A1 LUBRICATING COMPOSITIONS CONTAINING ISOPRENE BASED COMPONENTS CASTROL LIMITED (GB) 2016-05-19 US disclosed
US-20160137945-A1 LUBRICATING COMPOSITIONS CONTAINING ISOPRENE BASED COMPONENTS CASTROL LIMITED (GB) 2016-05-19 US disclosed
WO-2014207235-A1 LUBRICATING COMPOSITIONS CONTAINING ISOPRENE BASED COMPONENTS CASTROL LIMITED (GB) 2014-12-31 WO disclosed
US-8822187-B1 Polypeptides, nucleic acid molecules, and methods for synthesis of triterpenes UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2014-09-02 US disclosed
US-20060035873-A1 Methods for inducing apolipoprotein e secretion ILEX PRODUCTS, INC. 2006-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230321228-A1 VACCINE ADJUVANTS AND METHODS OF SYNTHESIZING AND USING THE SAME MYD88, TLR9, TLR5 KMT2A 4287/4885ALOX15 59/4885ALDH1A1 4529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.